Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)


Zofenopril, an inhibitor of the angiotensin-converting enzyme (ACE), has recently been widely introduced into the pharmaceutical market. Its clinical safety and efficacy has been demonstrated in patients with hypertension and in patients with acute myocardial infarction (AMI). The Survival of Myocardial Infarction Long-term Evaluation (SMILE) project provided valuable information regarding the safety of early onset ACE inhibition with zofenopril after AMI and a greater perception of the early and late benefits. The SMILE-I study demonstrated that most benefits of ACE inhibition may be obtained early after AMI and persist after discontinuation of treatment. The SMILE-II study demonstrated that early zofenopril treatment (initiated
Original languageDutch
Pages (from-to)631 - 647
JournalExpert Review of Cardiovascular Therapy
Issue number5
Publication statusPublished - 2006

Cite this